• BIIB
• JNJ
• LLY
• NBI
• NVO
• PFE
• US500

Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return

The biopharmaceutical industry seeks to rebound in 2025, navigating uncertainty from regulatory changes and potential impacts from President Trump's administration on drug pricing and vaccine policies.